Objective To explore the prognostic value of serum Sestrin2, lipoprotein⁃associated phospholipase A2 (Lp⁃PLA2) combined with miR-146a in predicting patients with septic cardiomyopathy. Methods Clinical data of 115 patients with septic cardiomyopathy were retrospectively analyzed. Patients were divided into death group (n=41) or survival group (n=74) according to their prognosis. Serum Sestrin2, Lp⁃PLA2, and miR⁃146a levels and clinical data were compared between the two groups. Multivariate Logistic regression model was used to analyze factors influencing the prognosis of patients with septic cardiomyopathy, and the prognostic value of serum Sestrin2, Lp⁃PLA2, and miR⁃146a for alone and jointly predicting patients with septic cardiomyopathy was evaluated using the receiver operating characteristic (ROC) curve. Results The serum Sestrin2, LP⁃PLA2, miR⁃146a levels, and white blood cell count, Acute Physiology and Chronic Health Evaluation Ⅱ (APACHEⅡ ) score, C⁃reactive protein level, as well as Sequential Organ Failure Assessment (SOFA) score at admission of the death group were higher than those of the survival group (P<0.05). Serum Sestrin2, serum LP⁃PLA2, serum miR⁃146a, and APACHEⅡ score at admission were independent risk factors for the prognosis of patients with septic cardiomyopathy (P<0.05). Areas under the curve (AUC) of serum Sestrin2, LP⁃PLA2, miR⁃146a levels alone and jointly for predicting death of patients with septic cardiomyopathy were 0.738, 0.796, 0.781, and 0.877, respectively (P<0.05), and the AUC of the combination of the three was higher (P<0.05). Conclusion Serum Sestrin2, Lp⁃PLA2 and miR⁃146a levels are of great value in predicting the prognosis of patients with septic cardiomyopathy, and their combined predictive value is higher.

无